Pain Management Conference 2004 -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the pain drug market offers biopharmaceutical companies significant commercial opportunity. The Company announced plans, at the Pain Management 2004 Conference in London, England today, to offer a new report portfolio dedicated to pain topics.

Because of its broad prevalence, high unmet clinical need, and favorable competitive environment, the pain drug market offers biopharmaceutical companies significant commercial opportunity:

  -- Chronic low back pain alone has a prevalence of more than 30 million in      the G7 markets.   -- Significant shortcomings in efficacy and tolerability/safety of current      pain therapeutics signal a significant need for novel pain products.   -- Pain agents in the pipeline have not been able to capitalize on the      unmet needs in the past decade leaving the door open for companies to      invest in pain resources.  

"Doctors can see a wound, they can't see pain. Pain is subjective and makes its impact across many indications," said Kate Hohenberg, therapeutic area director for Pain at Decision Resources. "Decision Resources' pain studies offer objective research to help pharmaceutical companies and biotechs understand the tremendous commercial opportunity in the pain drug market."

The Decision Resources' pain portfolio will offer a variety of studies and reports that give pharmaceutical companies and biotechs a comprehensive view of individual pain markets. The series will cover current and emerging therapies, and provide detailed patient-based market forecasts, and direct insights from physicians, managed care organizations, and patients.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Type 2 Diabetes Market to Exceed $15 Billion in 2013, Driven by Innovative Drugs

View Now